BIOSIMILARS

EXPANDING OPTIONS FOR PATIENT CARE

Extensive use of and growing demand for biologics come at a time when there is increasing need for savings and efficiencies for healthcare systems[1,2]



Biosimilars are highly similar in terms of safety and effectiveness to an existing biologic medicine, with no clinically meaningful differences[3]

Biosimilars are much more complex than small molecules and are created in living systems that require significant expertise and state-of-the-art technology[3,4]



Biosimilars are evaluated in **rigorous analytical, nonclinical, and clinical studies** to be licensed by the FDA[3]



ANALYTICAL

COMPARATIVE NONCLINICAL

COMPARATIVE CLINICAL PHARMACOLOGY PK/PD

COMPARATIVE CLINICAL

In certain cases, additional comparative clinical studies may be warranted to help ensure that there are no clinically meaningful differences between the products

Pfizer Biosimilars expands Pfizer's commitment to provide therapies that may improve the lives of patients, leveraging our expertise to deliver high-quality biosimilars[5,6]

11 Years of Experience With Biosimilars Outside the United States[7]

30+ Years of Experience With Biologics[7]

6 Biosimilars in Market in the United States[8]*

Biosimilars may offer additional treatment options that, after reference biologic patent expiry, may increase savings and efficiencies to healthcare systems and expand the use of biologic therapies[4]

- Additional treatment choices
- Possible healthcare system savings and efficiencies
- Variety of therapeutic options

*As of February 2020

For more information, please visit
PfizerBiosimilars.com

REFERENCES

1. Schumock GT, Stubbings J, Hoffman JM, et al. National trends in prescription drug expenditures and projections for 2019. *Am J Health Syst Pharm*. 2019;76(15):1105-1121.

2. Centers for Medicare & Medicaid Services. National Health Expenditure Projections 2018-2027. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ForecastSummary.pdf. Accessed March 20, 2020.

3. US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring, MD: FDA; 2015.

4. US Food and Drug Administration. Biosimilars Action Plan: Balancing Innovation and Competition. https://www.fda.gov/media/114574/download. Accessed March 20, 2020.

5. Pfizer Inc. Pfizer Pipeline. As of January 28, 2020. https://pfe-pfizercom-prod.s3.amazonaws.com/product-pipeline/Pipeline_Update_28JAN2020_Final-v2_0.pdf. Accessed April 20, 2020.

6. Pfizer Inc. Breakthroughs that change patients' lives. Pfizer 2019 Annual Review. https://www.pfizer.com/files/investors/financial_reports/annual_reports/2019/assets/pfizer-2019-annual-review.pdf. Accessed March 20, 2020.

7. Data on file. Pfizer Inc., New York, NY.

8. FDA-Approved Biosimilar Product Information. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed April 20, 2020.